Pharmaceutical stocks experienced broad declines in Tuesday's trading session. As of writing, Eli Lilly (LLY.US) led losses with a drop exceeding 2.9%. Sector peers Novo Nordisk (NVO.US) and Moderna (MRNA.US) both fell more than 2%, while Pfizer (PFE.US) declined over 1.7%. UnitedHealth Group (UNH.US) also saw significant pressure, sliding beyond 2.2% amid the sector-wide pullback. The downward movement reflects ongoing market repositioning within the healthcare segment without immediate catalysts cited for the collective weakness.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。